Overview

ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.

Since ChemoCentryx's founding in 1997, we believe we have established one of the broadest pipelines of chemokine-based therapeutics in the biopharmaceutical industry based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate inflammation. Each of our novel small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

The ChemoCentryx approach is designed to discover, develop and commercialize therapeutics that provide distinct advantages over currently marketed therapies in our disease areas of focus. These advantages include:

• Improved safety profile.
  Our product candidates are designed to selectively target only those chemokine-chemokine receptor interactions involved in a specific disease, rather than broadly suppressing the body's immune system. Existing treatments for autoimmune and inflammatory diseases tend to suppress the entire immune system which can lead to dangerous safety consequences.

• Convenient dosing and improved patient compliance.
  Our current product candidates are designed to be administered orally. Many marketed therapeutics for autoimmune diseases, inflammatory disorders and cancer are administered via injection or infusion.

• Lower production costs.
  Unlike biologic therapeutics, which tend to be expensive to produce, our current small molecule product candidates are typically less expensive to manufacture.

ChemoCentryx has internally generated several clinical- and preclinical-stage compounds, each targeting distinct chemokine receptors and offering the potential to treat various diseases. Our lead product candidate, Traficet-EN™, or CCX282, is intended to be a first-in-class, anti-inflammatory small molecule therapeutic targeting the CCR9 chemokine receptor. Traficet-EN is in a Phase II/III clinical trial for the treatment of patients with moderate-to-severe Crohn's disease, called PROTECT-1. This study is designed to evaluate Traficet-EN for the induction of clinical response or remission in patients with Crohn's disease as well as to evaluate Traficet-EN's utility as maintenance therapy. Traficet-EN is also in a Phase II proof-of-concept clinical trial for the treatment of patients with celiac disease. A second product candidate, CCX140, which targets the chemokine receptor CCR2, is being studied in a Phase I clinical trial. The CCR2 receptor is of central importance to inflammatory diseases, such as vascular restenosis and multiple sclerosis. CCX354, which targets the chemokine receptor CCR1, is our third product candidate currently in the clinic and is being studied in a Phase I clinical trial. CCR1 plays a significant role in rheumatoid arthritis and other inflammatory disorders. Our fourth investigational new drug in clinical trials is CCX025 which is the second orally administered compound that inhibits the CCR9 chemokine receptor.

Programs in advanced preclinical development include:

• Our C5a chemo-attractant receptor antagonist series, a potential source of product candidates for the treatment of age-related macular degeneration, rheumatoid arthritis, systemic lupus erythematosus and other inflammatory disorders;
• Anticancer compounds that target CXCR7, a chemokine receptor associated with tumor growth; and
• Additional compounds under evaluation targeting novel chemokine receptors such as CCR5, CCR10, CCR12, CXCR2 and CXCR4.

ChemoCentryx has developed a purpose-built suite of proprietary drug discovery technologies, called EnabaLink^®. This technology suite is specifically designed to unlock the chemokine system's complexity and to accelerate a productive drug discovery program. ChemoCentryx has leveraged the EnabaLink drug discovery engine to identify and optimize each of our clinical and preclinical product candidates.

We believe that our broad pipeline of oral product candidates and development compounds, our ability to advance unique, highly specific compounds into and through clinical development across diverse indications, and our proprietary drug discovery technologies provide us with distinct advantages that will enable us to continue to discover and develop novel therapeutics for the treatment of chronic diseases.

^ Return to Top